Perna G, Cogo R, Bellodi L.
Selective serotonin re-uptake inhibitors beyond psychiatry: are they useful in the treatment of severe, chronic, obstructive pulmonary disease?
Depress Anxiety. 2004;20(4):203-4.

Erzegovesi S, Guglielmo E, Siliprandi F, Bellodi L.
Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study.
Eur Neuropsychopharmacol. 2005 Jan;15(1):69-74.

Erzegovesi S, Riboldi C, Di Bella D, Di Molfetta D, Mapelli F, Negri B, Tenace M, Bellodi L.
Bulimia nervosa, 5-HTTLPR polymorphism and treatment response to four SSRIs: a single-blind study.
J Clin Psychopharmacol. 2004 Dec;24(6):680-2.

Cavedini P, Bassi T, Zorzi C, Bellodi L.
The advantages of choosing antiobsessive therapy according to decision-making functioning.
J Clin Psychopharmacol. 2004 Dec;24(6):628-31.

Bertani A, Perna G, Migliarese G, Di Pasquale D, Cucchi M, Caldirola D, Bellodi L
Comparison of the treatment with paroxetine and reboxetine in panic disorder: a randomized, single-blind study.
Pharmacopsychiatry. 2004 Sep;37(5):206-10.

Bertani A, Perna G, Migliarese G, Di Pasquale D, Cucchi M, Caldirola D, Bellodi L
Comparison of the treatment with paroxetine and reboxetine in panic disorder: a randomized, single-blind study.
Pharmacopsychiatry. 2004 Sep;37(5):206-10.

Bareggi SR, Bianchi L, Cavallaro R, Gervasoni M, Siliprandi F, Bellodi L.
Citalopram concentrations and response in obsessive-compulsive disorder. Preliminary results.
CNS Drugs. 2004;18(5):329-35.

Mundo E, Pirola R, Bellodi L, Smeraldi E, Bareggi SR.
Are gender differences in antiobsessional response related to different clomipramine metabolism?
J Clin Psychopharmacol. 2002 Jun;22(3):341-2.

Perna G, Bertani A, Caldirola D, Gabriele A, Cocchi S, Bellodi L.
Antipanic drug modulation of 35% CO2 hyperreactivity and short-term treatment outcome.
J Clin Psychopharmacol. 2002 Jun;22(3):300-8.

Pirola R, Mundo E, Bellodi L, Bareggi SR.
Simultaneous determination of clomipramine and its desmethyl and hydroxy metabolites in plasma of patients by high-performance liquid chromatography after solid-phase extraction.
J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Jun 5;772(2):205-10.

Di Bella D, Erzegovesi S, Cavallini MC, Bellodi L.
Obsessive-Compulsive Disorder, 5-HTTLPR polymorphism and treatment response.
Pharmacogenomics J. 2002;2(3):176-81.

Mundo E, Pirola R, Bellodi L, Smeraldi E, Bareggi SR.
Are gender differences in antiobsessional response related to different clomipramine metabolism?
J Clin Psychopharmacol. 2002 Jun;22(3):341-2.

Perna G, Bertani A, Caldirola D, Gabriele A, Cocchi S, Bellodi L.
Antipanic drug modulation of 35% CO2 hyperreactivity and short-term treatment outcome.
J Clin Psychopharmacol. 2002 Jun;22(3):300-8.

Pirola R, Mundo E, Bellodi L, Bareggi SR.
Simultaneous determination of clomipramine and its desmethyl and hydroxy metabolites in plasma of patients by high-performance liquid chromatography after solid-phase extraction.
J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Jun 5;772(2):205-10.

Di Bella D, Erzegovesi S, Cavallini MC, Bellodi L.
Obsessive-Compulsive Disorder, 5-HTTLPR polymorphism and treatment response.
Pharmacogenomics J. 2002;2(3):176-81.

Cavedini P, Erzegovesi S, Ronchi P, Bellodi L.
Predictive value of obsessive-compulsive personality disorder in antiobsessional pharmacological treatment.
Eur Neuropsychopharmacol. 1997 Feb;7(1):45-9.

Erzegovesi S, Martucci L, Henin M, Bellodi L.
Low versus standard dose mCPP challenge in obsessive-compulsive patients.
Neuropsychopharmacology. 2001 Jan;24(1):31-6.

Bajo S, Battaglia M, Pegna C, Bellodi L.
Citalopram and fluvoxamine in Tourette's disorder.
J Am Acad Child Adolesc Psychiatry. 1999 Mar;38(3):230-1

Mundo E, Ronchi P, Bellodi L.
Drug-induced mania.
Hosp Community Psychiatry. 1993 Jul;44(7):689-90.